| P50 | author | Jillian L Shaw | Q86427054 |
| | Anna Greka | Q89564393 |
| | Abhigyan Satyam | Q60220127 |
| P2093 | author name string | Seth L Alper | |
| | Rebecca Thompson | |
| | Katherine A Vernon | |
| | George C Tsokos | |
| | Keith Keller | |
| | Astrid Weins | |
| | Ayshwarya Subramanian | |
| | Juan Gutierrez | |
| | Frederick W K Tam | |
| | Brian T Chamberlain | |
| | Andrew Watts | |
| | Moran Dvela-Levitt | |
| | Julie Roignot | |
| | Florence Wagner | |
| | Stephen P McAdoo | |
| | Juan Lorenzo Pablo | |
| | Choah Kim | |
| | Juliana Coraor | |
| | Michelle Melanson | |
| | Valeria Padovano | |
| | Maria Alimova | |
| | Lucienne Ronco | |
| | Abbe Clark | |
| | Jean Santos | |
| | Jamie Marshall | |
| | Eriene-Heidi Sidhom | |
| | Maheswarareddy Emani | |
| | Alissa Campbell | |
| | Elizabeth Grinkevich | |
| | Matthew Racette | |
| | Silvana Bazua-Valenti | |
| | Estefania Reyes Bricio | |
| P2860 | cites work | A novel lung injury animal model using KL-6-measurable human MUC1-expressing mice | Q86120530 |
| | Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study | Q87412594 |
| | An interactive web-based dashboard to track COVID-19 in real time | Q87456354 |
| | Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China | Q87759574 |
| | A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | Q88370045 |
| | The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality | Q90799655 |
| | Compassionate Use of Remdesivir for Patients with Severe Covid-19 | Q91807066 |
| | Cytokine release syndrome in severe COVID-19 | Q92024546 |
| | Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model | Q92035548 |
| | Serum KL-6 levels in Pulmonary Langerhans' Cell Histiocytosis | Q92054304 |
| | Small Molecule Targets TMED9 and Promotes Lysosomal Degradation to Reverse Proteinopathy | Q92204301 |
| | MUC1 contributes to goblet cell metaplasia and MUC5AC expression in response to cigarette smoke in vivo | Q94657212 |
| | Functional roles of Syk in macrophage-mediated inflammatory responses | Q26851134 |
| | An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis | Q28294375 |
| | The Drug Repurposing Hub: a next-generation drug library and information resource | Q29363901 |
| | Drug repositioning: identifying and developing new uses for existing drugs | Q29614779 |
| | Proteomics. Tissue-based map of the human proteome | Q29617248 |
| | High-Throughput RT-PCR for small-molecule screening assays | Q30457502 |
| | Fostamatinib Disodium. | Q33405080 |
| | Getting Syk: spleen tyrosine kinase as a therapeutic target. | Q33993750 |
| | Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN. | Q34260045 |
| | Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial | Q34443454 |
| | Epidemiological studies in mucus hypersecretion. | Q35060120 |
| | Antagonistic regulation of cystic fibrosis transmembrane conductance regulator cell surface expression by protein kinases WNK4 and spleen tyrosine kinase | Q35274006 |
| | The SYK tyrosine kinase: a crucial player in diverse biological functions | Q36662082 |
| | Spleen tyrosine kinase induces MUC5AC expression in human airway epithelial cell | Q38786029 |
| | A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis | Q39485380 |
| | Macrophage-derived interleukin-6 up-regulates MUC1, but down-regulates MUC2 expression in the human colon cancer HT-29 cell line | Q39886148 |
| | Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome. | Q40120539 |
| | Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials | Q40699579 |
| | Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion | Q42623005 |
| | Discovery and development of spleen tyrosine kinase (SYK) inhibitors | Q46049320 |
| | MUC1: The First Respiratory Mucin with an Anti-Inflammatory Function | Q47696532 |
| | Design, synthesis of diaminopyrimidine inhibitors targeting IgE- and IgG-mediated activation of Fc receptor signaling | Q48085136 |
| | Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. | Q51655192 |
| | Fostamatinib for the Treatment of Adult Persistent and Chronic Immune Thrombocytopenia: Results of Two Phase 3, Randomized, Placebo-Controlled Trials. | Q52562217 |
| | Immunohistochemical and immunoelectron microscopic studies of the localization of KL-6 and epithelial membrane antigen (EMA) in presumably normal pulmonary tissue and in interstitial pneumonia. | Q53510494 |
| | Fostamatinib for persistent/chronic adult immune thrombocytopenia. | Q54144290 |
| | The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice. | Q54579373 |
| | Drug repurposing: progress, challenges and recommendations | Q57471980 |
| P921 | main subject | acute lung injury | Q4677935 |
| | COVID-19 | Q84263196 |
| | COVID-19 pandemic | Q81068910 |
| P577 | publication date | 2020-06-30 | |
| P1476 | title | A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic | |